ViiV Secures Its First New Drug Approval With Tivicay
This article was originally published in The Pink Sheet Daily
Executive Summary
The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.